AstraZeneca Removes Early Degrader and Hematology Programs
AstraZeneca’s pipeline updated 30 October lists AZD9750, an androgen-receptor PROTAC for prostate cancer, and AZD2962, an IRAK4 inhibitor for hematologic malignancies, among projects removed since last quarter. The removal is verified; the public pipeline…
